The development of engineered cardiac tissues has substantially advanced our understanding of cardiac disease mechanisms and enhanced the predictive accuracy of therapeutic screening for cardiomyopathies. In arrhythmogenic cardiomyopathy (ACM), an inh...
The development of engineered cardiac tissues has substantially advanced our understanding of cardiac disease mechanisms and enhanced the predictive accuracy of therapeutic screening for cardiomyopathies. In arrhythmogenic cardiomyopathy (ACM), an inherited disorder characterized by defective intercellular adhesion and mislocalization of connexin-43 (Cx43) resulting from mutations in desmosomal proteins such as plakophilin-2 (PKP2) and plakoglobin (PKG), the alignment of cardiomyocytes plays a critical role in determining electrical propagation and therapeutic outcomes. To investigate the influence of myocardial anisotropy on ACM phenotypes, we fabricated cardiac tissue chips using human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) and neonatal rat ventricular myocytes (NRVMs). These cells were cultured on micromolded gelatin substrates that reproduced longitudinal, transverse, and isotropic myocardial architectures. Tissues carrying PKP2 or PKG mutations exhibited characteristic ACM features, including slowed conduction, disrupted Cx43 localization, and elevated arrhythmic susceptibility. Treatment with the glycogen synthase kinase-3β inhibitor SB216763 effectively restored Cx43 organization and conduction velocity, most prominently in longitudinally aligned tissues, whereas its efficacy was limited in transverse and isotropic constructs. These findings underscore the importance of incorporating physiological myocardial anisotropy into engineered cardiac models to faithfully recapitulate ACM pathophysiology and improve the reliability of therapeutic screening. This approach provides a promising foundation for precision medicine by enabling more accurate predictions of therapeutic efficacy and patient-specific treatment responses in ACM.